Daratumumab

Daratumumab is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It belongs to a class of drugs known as monoclonal antibodies.

Daratumumab works by targeting a protein called CD38, which is found on the surface of myeloma cells. By binding to CD38, daratumumab activates the immune system to attack and destroy the cancer cells. It can also induce direct cell death and inhibit the growth of myeloma cells.

The medication is typically administered intravenously and may be used in combination with other chemotherapy drugs or immunomodulatory agents for the treatment of multiple myeloma. The specific dosage and treatment regimen are determined by the healthcare provider based on the individual’s condition, response to therapy, and other factors.

Common side effects of daratumumab may include infusion-related reactions, fatigue, diarrhea, upper respiratory tract infections, and low blood cell counts. More serious side effects, such as infections or infusion-related allergic reactions, can occur but are less common. Regular monitoring of blood cell counts and other parameters may be recommended during treatment.

Daratumumab should only be used under the guidance and prescription of a qualified healthcare professional experienced in the treatment of multiple myeloma. It may interact with other medications, so it is important to inform the healthcare provider about all medications being taken, including over-the-counter drugs and supplements.

In summary, daratumumab is a medication used in the treatment of multiple myeloma. It targets the CD38 protein on myeloma cells to induce immune-mediated cell death. Regular monitoring and adherence to healthcare provider instructions are important during daratumumab treatment.

Note – The brand names and product descriptions used on this site are for informational purposes only and are the property of their respective owners.